Axomove announced it has raised €4 million in a Series A funding round to accelerate the deployment of its digital medical device focused on prevention and rehabilitation, particularly for chronic conditions such as low back pain.
The round was co-led by the Digital Prevention Fund, managed by Bpifrance, and GO CAPITAL, with participation from INCO Ventures and existing investor Faraday Venture Partners.
Axomove has developed a digital therapeutic solution designed to support patients through movement-based prevention and rehabilitation programs. The company says its platform is currently the only solution in its category reimbursed by national health insurance for chronic low back pain, positioning it uniquely within the digital health landscape.
The funding will support Axomove’s next phase of growth, including expanding commercial deployment across companies, insurers, and healthcare institutions. The company also plans to broaden its therapeutic scope beyond back pain into additional musculoskeletal conditions such as osteoarthritis, as well as metabolic conditions, with a focus on obesity management.
Axomove aims to improve patient outcomes and healthcare pathways by delivering scalable, accessible digital care solutions that emphasize prevention and long-term health management. The company’s approach reflects a broader shift toward digital therapeutics and value-based care models that prioritize continuous engagement and measurable health outcomes.
With the new capital, Axomove is positioning itself to scale its platform, deepen partnerships across the healthcare ecosystem, and expand reimbursement coverage for a wider range of conditions.
